I'm willing to roll the dice and take a big gamble, but I have some insight that may help get your product moving. You have something your competition doesn't and I can help you leverage that.
I love this guy. If you're talking about the sprinkle indication, nobody gives a flying fart about that. Plus they can sprinkle too. Come on and show us how it's done, big boy!
Qudexy has clinical trials showing fewer AEs than IR topiramate. It's still a QD option regardless of the PK profile. It offers a zero copay with the same coverage as Trokendi XR. Qudexy also provides samples to get patients started immediately. When you figure out how to leverage all those things, how quickly the game will change. You need people to buy into that belief and things will change!
Thx for the game changing insight. Can't believe the key to Turning the tides was right in front of us the whole time. How can we thank you prophet full of wisdom? How about the fact we were late to the party with completely inept leadership. Your genius will unfortunately go unnoticed, but thanks for the tidbit loser
Loser? Have you looked in the mirror lately dipshit? Your attitude is the reason why you fail. You can point your finger and say "it's the leaderships fault and Trokendi XR was first to the market". You sound like a whining little bitch. If you already knew the answer to which I previously stated then why isn't your market share growing? I would have to say it's because there are people like you on the pay roll. You don't know what it's like to go out and hustle and grind it out. That's the difference between upsher and Supernus. Your lazy mindset needs to change if you want your market to change. P.S. You're welcome for my insight!
As of now, qudexy has been a miserable failure, it could still turn around...the tooth fairy could be real too.
the company motto seems to be "better to be lucky than be good". They have no business being in brands as they don't have the stomach for competition. Always looking for an angle and a short cut. Lots of big talk without anything to back it up. sounds like it's back to generics at least for this quarter.